Market Expansion Outlook Therapeutics is actively expanding its presence in Europe, having recently increased office footprint and secured Scottish Medicines Consortium approval for LYTENAVA™. This indicates a promising market opportunity in the EU and UK for ophthalmic treatments of wet AMD.

Regulatory Advancements The company has achieved regulatory approval in the EU and UK for LYTENAVA™, and has resubmitted the BLA to the FDA for the U.S., paving the way for potential future sales in multiple major markets for ophthalmic retinal treatments.

Innovative Product Pipeline With LYTENAVA™ being the first ophthalmic formulation of bevacizumab approved for retinal diseases, Outlook offers a differentiated product that can position it strongly against competitors in the retina therapeutics space.

Leadership Momentum Recent executive appointments, including hiring a Vice President for Corporate Strategy and a new Chairman of the Board, signal a strategic focus on growth and market penetration, which can facilitate business development efforts.

Market Focus and Trends Outlook focuses on wet AMD treatment, a large and growing retinal disease market. Its innovative formulation and international approvals present a compelling value proposition for healthcare providers and distributors seeking novel ophthalmic solutions.